Video
Current developments in PSMA research
Author(s):
“I believe we are getting to an era where we will be able to cure a significant subset of patients who we are not able to cure today,” says Neil H. Bander, MD.
Video Player is loading.
In this video, Neil H. Bander, MD, shares his perspective on what the future of prostate-specific membrane antigen (PSMA) research will look like as well as what current developments are taking place. Bander is the Bernard & Josephine Chaus professor of urologic oncology at Weill Cornell Medicine, New York City, New York.
Related Videos
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Jason Hafron, MD, considers the future for AI in urology
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
Investigators evaluate tamsulosin use in pediatric patients
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
Related Content
